Publications     News     About    Contact

Solutions & Services

Therapeutic expertise

Why APICES

Meet us at ASCO
Genitourinary Cancers Symposium 2026

APICES will be at ASCO GU 2026 in San Francisco, bringing experience from 50+ genitourinary oncology studies to support biotech and pharma partners across European clinical development. Meet the team on site.

Execution first

APICES supports sponsors when clinical plans are tested by execution. We focus on reducing risk early, before timelines slip, sites underperform, or assumptions require correction mid-study. Our work is grounded in how clinical trials are actually delivered in Europe.

Solutions

Services

Therapeutic areas

About us

Why APICES?

Why APICES

APICES helps sponsors make better clinical decisions earlier, combining strategic insight with hands-on European execution to protect timelines, budgets, and outcomes.

Clinical Trials

Patients Enrolled

Clinical Sites

Acknowledgements

We take responsibility

We view responsible clinical research as more than compliance alone. APICES operates in accordance with applicable GCP and European regulatory standards, with sustainability and ESG principles integrated into how we work and make decisions.

“Clinical trials succeed when experience leads decisions, assumptions are tested early, and execution stays accountable from protocol to last patient.”

How we support

Trials rarely lose momentum in one dramatic moment. It usually starts quietly. Start-up takes longer than expected. Sites underperform or slowly drift off plan. Updates feel filtered, not actionable. Decisions arrive too late to correct course. Risk accumulates in the background until timelines slip and confidence erodes.

Apices exists to stop that slide, before small issues turn into expensive delays.

Early Clinical Development

When moving from protocol to first European execution →

Late Clinical Development

When scale, consistency, and delivery discipline matter →

RWE & HEOR

When outcomes data is required beyond controlled trials →

Medical Devices

When clinical evidence must support European regulatory and market needs →

What makes it work

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

 

  1. Senior-led teams with direct sponsor access
  2. Clear ownership from day one
  3. European regulatory and site experience
  4. No layers. No hand-offs.
  5. Focus on delivery, not volume

Case Study

Phase I/IIa Oncology: Fast European Execution Under Tight Timelines

The successful delivery of this Phase I/IIa study positioned the sponsor to confidently progress to the next stages of clinical development.

Talk before things get complicated

If you are preparing an RFI or RFP, or feel a study is about to hit its apex moment, talk to the people who would actually run it.